Closely-held Zucara Therapeutics’ positive proof-of-concept data has enabled the company to secure continued funding for a Phase 2 clinical study of ZT-01 to prevent hypoglycemia in people with Type 1 diabetes, which is...
Profound Medical (NASDAQ:PROF; TSX:PRN) has changed its management team and structure to further position the company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed...
OpSens (TSX:OPS; OTCQX:OPSSF) received 510(k) regulatory clearance from the FDA for SavvyWire, its new guidewire for transcatheter aortic valve replacement procedures, or TAVR. In a statement, Louis Laflamme, president...
Hepion Pharmaceuticals’ (NASDAQ:HEPA) collaborators from London’s Institute of Hepatology will present new findings on Hepion’s cyclophilin inhibitor, rencofilstat, in an awarded oral presentation at the...
Annovis Bio (NYSE:ANVS) announced the publication of three granted U.S. patents that cover methods of treating amyloid lateral sclerosis, Huntington’s disease, and prion diseases by administering buntanetap. The...
Fresh Tracks Therapeutics (NASDAQ:FRTX), formerly Brickell Biotech, initiated the multiple ascending dose (MAD) portion of the ongoing Phase 1 clinical trial in Canada, evaluating FRTX-02, its lead drug candidate, in...
Hepion Pharmaceuticals (NASDAQ:HEPA) dosed the first stage 3 (F3) NASH subject with rencofilstat in a Phase 2 clinical trial designed to measure hepatic function. The trial is being conducted in collaboration with...
POINT Biopharma Global (NASDAQ:PNT) published a poster at ESMO Congress 2022 containing updated efficacy and safety data from the 27-patient safety and dosimetry lead-in cohort for the company’s Phase 3 SPLASH...
Vistagen Therapeutics (NASDAQ:VTGN) announced completion of an interim analysis of PALISADE-2, its second Phase 3 clinical trial assessing drug candidate, PH94B, as an acute treatment of anxiety in adults with social...